Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (5)

Search Parameters:
Keywords = percutaneous deep venous arterialization

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
19 pages, 4394 KB  
Case Report
A Sole Case of Concurrent Arterial and Venous Thromboses with Massive Pulmonary Embolism and Carriage of Four Genetic Polymorphisms: Factor V Leiden, PAI-1 4G/5G, MTHFR C677T, and ACE I/D—A Case Report
by Nevena Ivanova
Reports 2025, 8(3), 167; https://doi.org/10.3390/reports8030167 - 1 Sep 2025
Cited by 1 | Viewed by 4313
Abstract
Background and Clinical Significance: Arterial and venous thromboses are typically distinct clinical entities, each governed by unique pathophysiological mechanisms. The concurrent manifestation of both, particularly in the setting of massive pulmonary embolism (PE), is exceptionally rare and poses significant diagnostic and therapeutic challenges. [...] Read more.
Background and Clinical Significance: Arterial and venous thromboses are typically distinct clinical entities, each governed by unique pathophysiological mechanisms. The concurrent manifestation of both, particularly in the setting of massive pulmonary embolism (PE), is exceptionally rare and poses significant diagnostic and therapeutic challenges. Case Presentation: This report describes a 61-year-old male with well-controlled hypertension and type 2 diabetes who developed extensive thromboses involving deep vein thrombosis (DVT) of the right popliteal vein, arterial thrombosis of the left iliac artery, and massive PE. The patient was initially managed conservatively, in accordance with the European Society of Cardiology (ESC) 2019 Guidelines for Acute PE, using unfractionated heparin (UFH), low-molecular-weight heparin, a direct oral anticoagulant (DOAC), and adjunctive therapy. This approach was chosen due to the absence of hemodynamic instability. However, given failed percutaneous revascularization and persistent arterial occlusion, surgical thromboendarterectomy (TEA) was ultimately required. Post hoc genetic testing was prompted by the complex presentation in the absence of classical provoking factors—such as trauma, surgery, malignancy, or antiphospholipid syndrome—consistent with recommendations for selective thrombophilia testing in atypical or severe cases. The analysis revealed four thrombophilia-associated polymorphisms: heterozygous Factor V Leiden (FVL; R506Q genotype), Plasminogen Activator Inhibitor-1 (PAI-1; 4G/5G genotype), Methylenetetrahydrofolate reductase (MTHFR; c.677C > T genotype), and homozygous Angiotensin-Converting Enzyme Insertion/Deletion (ACE I/D; DD genotype). Conclusions: While each variant has been individually associated with thrombotic risk, their co-occurrence in a single patient with simultaneous arterial and venous thromboses has not, to our knowledge, been previously documented. This case underscores the potential for gene–gene interactions to amplify thrombotic risk, even in the presence of variants traditionally considered to confer only modest to moderate risk. It highlights the need for a multidisciplinary approach and raises questions regarding pharmacogenetics, anticoagulation, and future research into cumulative genetic risk in complex thrombotic phenotypes. Full article
Show Figures

Figure 1

10 pages, 1467 KB  
Review
Percutaneous Deep Venous Arterialization for Limb Salvage in No Option Patients with Chronic Limb-Threatening Ischemia
by Stavros Spiliopoulos, Efstathia Davoutis, Nikolaos-Achilleas Arkoudis, Kaji Sritharan and Symeon Lechareas
J. Clin. Med. 2023, 12(23), 7324; https://doi.org/10.3390/jcm12237324 - 26 Nov 2023
Cited by 6 | Viewed by 3556
Abstract
An endovascular approach is often considered the first line treatment option for lower limb chronic limb-threatening ischemia (CLTI), which is defined by the presence of ischemic rest pain and severe tissue loss, such as ulcers or gangrene. Although the technical success rate of [...] Read more.
An endovascular approach is often considered the first line treatment option for lower limb chronic limb-threatening ischemia (CLTI), which is defined by the presence of ischemic rest pain and severe tissue loss, such as ulcers or gangrene. Although the technical success rate of endovascular revascularization is high, in specific patients with advanced infrapopliteal disease and the absence of run-off tibial vessels, the so-called ‘desert foot’, the chance of successful endovascular revascularization is minimal. In order to avoid primary amputation, several treatment options are currently being investigated, including gene therapy and deep venous arterialization. This review focuses on the percutaneous deep venous arterialization technique as a promising, minimally invasive treatment option for limb salvage in CLTI patients presenting with a ‘desert foot’. Full article
(This article belongs to the Section Vascular Medicine)
Show Figures

Figure 1

11 pages, 798 KB  
Article
Development of a Prediction Model for the Occurrence of Stenosis or Occlusion after Percutaneous Deep Venous Arterialization
by Eline Huizing, Michiel A. Schreve, Steven Kum, Grigorios Papageorgiou, Jean-Paul P. M. de Vries, Gert J. de Borst and Çağdaş Ünlü
Diagnostics 2021, 11(6), 1008; https://doi.org/10.3390/diagnostics11061008 - 31 May 2021
Cited by 8 | Viewed by 2695
Abstract
Percutaneous deep venous arterialization (pDVA) is a promising treatment option in patients with chronic limb-threatening ischemia. Stenosis and occlusions, which are the Achilles’ heel of every revascularization procedure, can be treated when detected early. However, frequent monitoring after pDVA is required because when [...] Read more.
Percutaneous deep venous arterialization (pDVA) is a promising treatment option in patients with chronic limb-threatening ischemia. Stenosis and occlusions, which are the Achilles’ heel of every revascularization procedure, can be treated when detected early. However, frequent monitoring after pDVA is required because when stenosis or occlusions develop is unknown. Therefore, patients currently need to visit the hospital every 2 weeks for surveillance, which can be burdensome. Accordingly, we aimed to develop a model that can predict future stenosis or occlusions in patients after pDVA to be able to create tailor-made follow-up protocols. The data set included 343 peak systolic velocity and 335 volume flow measurements of 23 patients. A stenosis or occlusion developed in 17 patients, and 6 patients remained lesion-free. A statistically significant increase in the risk of stenosis or occlusion was found when duplex ultrasound values decreased 20% within 1 month. The prediction model was also able to estimate a patient-specific risk of future stenosis or occlusions. This is promising for the possibility of reducing the frequency of follow-up visits for low-risk patients and increasing the frequency for high-risk patients. These observations are the starting point for individual surveillance programs in post-pDVA patients. Future studies with a larger cohort are necessary for validation of this model. Full article
(This article belongs to the Special Issue Peripheral Arterial Disease: Diagnosis, Treatment and Follow-Up)
Show Figures

Figure 1

11 pages, 999 KB  
Article
Volume Flow and Peak Systolic Velocity of the Arteriovenous Circuit in Patients after Percutaneous Deep Venous Arterialization
by Michiel A. Schreve, Eline Huizing, Steven Kum, Jean-Paul P. M. de Vries, Gert J. de Borst and Çağdaş Ünlü
Diagnostics 2020, 10(10), 760; https://doi.org/10.3390/diagnostics10100760 - 28 Sep 2020
Cited by 12 | Viewed by 5386
Abstract
Percutaneous deep venous arterialization (pDVA) is a developing technique for limb salvage in patients with chronic limb-threatening ischemia by creating an arteriovenous (AV) circuit. After pDVA, patency of the AV circuit is evaluated using duplex ultrasound (DUS) imaging. Peak systolic velocity (PSV) and [...] Read more.
Percutaneous deep venous arterialization (pDVA) is a developing technique for limb salvage in patients with chronic limb-threatening ischemia by creating an arteriovenous (AV) circuit. After pDVA, patency of the AV circuit is evaluated using duplex ultrasound (DUS) imaging. Peak systolic velocity (PSV) and volume flow (VF) values for maintaining a patent AV circuit are undefined; therefore, guidance about when a reintervention should be performed is lacking. The objective of this study was to interpret post-pDVA PSV and VF values in relation to AV circuit preservation. This was performed by analyzing DUS results of 22 post-pDVA patients. A total of 670 PSV and 623 VF measurements were collected. A PSV value of ≤55 cm/s and a VF value of ≤195 mL/min were found predictive for failure. The reliability of PSV and VF measurements in patent AV-circuits was good (intraclass correlation coefficient; PSV, 0.85; VF, 0.88). In conclusion, this study is the first to analyze DUS measurements in post-pDVA patients and showed that DUS can be used to anticipate for failure. The thresholds found can be used to help interpret DUS measurements in post-pDVA patients. More research in a larger patient population is needed to prospectively validate these thresholds. Full article
(This article belongs to the Section Pathology and Molecular Diagnostics)
Show Figures

Graphical abstract

8 pages, 271 KB  
Editorial
Fondaparinux: A New Antithrombotic Treatment Strategy in Venous Thromboembolism and Acute Coronary Syndromes
by Jean-Pierre Bassand
Cardiovasc. Med. 2008, 11(9), 278; https://doi.org/10.4414/cvm.2008.01350 - 26 Sep 2008
Viewed by 393
Abstract
Fondaparinux (Arixtra®) is a synthetic selective factor Xa inhibitor. On the grounds of its favorable benefit-risk ratio, fondaparinux is approved for the prevention and treatment of venous thromboembolism. Two large trials in about 32000 patients recently evaluated fondaparinux in the treatment [...] Read more.
Fondaparinux (Arixtra®) is a synthetic selective factor Xa inhibitor. On the grounds of its favorable benefit-risk ratio, fondaparinux is approved for the prevention and treatment of venous thromboembolism. Two large trials in about 32000 patients recently evaluated fondaparinux in the treatment of non-ST elevation acute coronary syndromes and ST elevation acute myocardial infarction. Fondaparinux was compared with enoxaparin or usual care, depending on the setting. A single once-daily 2.5 mg subcutaneous dose of fondaparinux was used in both studies. After a brief presentation of the drug, this review presents the results obtained in these trials with fondaparinux and compares them with those obtained with other anticoagulants. Overall, it appears that fondaparinux at the single oncedaily dose of 2.5 mg represents a valuable new alternative for the treatment of patients with acute coronary syndromes. However, fondaparinux cannot be used as stand-alone anticoagulant in the setting of PCI, where an additional of unfractionated heparin is needed to eliminate the risk of catheter thrombus. Full article
Show Figures

Figure 1

Back to TopTop